Shortage of Eli Lilly's Zepbound and Mounjaro Drug Doses Continues as FDA Issues Supply Warning
Wednesday, 17 April 2024, 15:23
Update on Eli Lilly's Zepbound and Mounjaro Shortage
The recent FDA report highlighted the continued shortage of doses of Eli Lilly's Zepbound and Mounjaro drugs.
Supply Constraints Through June
The demand for weight loss and diabetes medications continues to outpace the available supply, posing challenges for patients and healthcare providers.
- Impact on Patient Care: The shortage can affect patient access to crucial medications.
- Manufacturers' Response: Eli Lilly and Novo Nordisk are working to increase production capacity to address the supply constraints.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.